Journal of Clinical Oncology
Articles in this Issue
Defining second-line sequencing in advanced renal cell carcinoma: A systematic review and meta-analysis.
4539 Background: In the absence of head-to-head comparative trials, the optimal sequencing of second-line systemic therapy...
Conversion therapy with PD-1/PD-L1 inhibitors plus gemcitabine-based chemotherapy for initially unresectable locally advanced gallbladder cancer.
e16272 Background: Locally advanced, initially unresectable gallbladder cancer (GBC) is associated with a poor prognosis....
Organotropic and genomic characterization of pancreatic neuroendocrine carcinoma.
4172 Background: Pancreatic neuroendocrine carcinoma (PNEC) is a rare, aggressive malignancy. Neuroendocrine carcinomas (N...
Optimizing PRRT sequencing after progression on somatostatin analogue in neuroendocrine tumors: A real-world analysis.
e16330 Background: Optimal sequencing of peptide receptor radionuclide therapy (PRRT) following progression on somatostati...
From chemotherapy to checkpoints: Survival trends in rectal adenocarcinoma.
e15594 Background: Colorectal cancer is the fourth most common malignancy worldwide and the second leading cause of cancer...
Potential of urine liquid biopsy in detecting of clinically relevant genomic alterations in advanced genitourinary cancers.
e17133 Background: Liquid biopsy has transformed molecular profiling through non-invasive detection of tumor-derived genom...
Factors associated with clinical trial failure and termination in non–small cell lung cancer immunotherapy: A ten-year review.
11116 Background: Immunotherapy (IO) has transformed NSCLC management, yet trial efficiency and strategy-level success pat...
Mortality trends of the leading cancers in Brazil: Real-world evidence from a national data platform.
e23421 Background: Cancer is a leading cause of mortality worldwide, with substantial variation by tumor type and region....
Trends in breast cancer stage at diagnosis over two decades in Côte d’Ivoire.
e22510 Background: In Côte d’Ivoire, late-stage breast cancer diagnosis remains a leading cause of poor outcomes. National...
Efficacy and safety of CAR T-cell therapy in hematologic malignancies: A systematic review and meta-analysis.
e18575 Background: CAR T-cell therapy has shown promise in treating relapsed/refractory hematologic malignancies. To compr...
Prevalence, genomic landscape, and outcomes of HRD and HRR alterations in solid tumors: Real-world data from western India.
e15207 Background: HRD and HRR alterations are key predictive and prognostic biomarkers in solid tumors, guiding targeted...
Feasibility of constructing an external control arm for early efficacy assessment in phase 1a: Methodological framework from the INVOKE trial.
11521 Background: Phase 1a dose-escalation trials are primarily designed for safety but often lack sufficient visibility i...
T-cell stem-like memory cells as a novel biomarker to identify patients with sustained disease control during treatment with PD-(L)1 immunotherapy.
2578 Background: Reliable, clinically easily testable biomarkers to monitor the benefit of treatment with immune checkpoin...
Systematic modeling of tumor-microenvironment–mediated NK cell dysfunction in pancreatic cancer to identify KLRB1 as a target for cell engineering.
e14541 Background: Adoptively transferred natural killer (NK) cells fail in pancreatic ductal adenocarcinoma (PDAC) due to...
Clinical experience–based assessment of informed consent forms written by generative artificial intelligence.
e13717 Background: The OpenEvidence (OE) generative artificial intelligence (AI) platform has emerged as a purpose-built t...
A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
4212 Background: Concurrent inhibition of GSK-3β and TGF-β signaling pathways aims to target epithelial-mesenchymal transi...
A randomized phase II clinical trial on intratumoral autologous CD1c (BDCA-1) <sup>+</sup> /CD141 (BDCA-3) <sup>+</sup> myeloid dendritic cells (myDC) plus ipilimumab (IPI) and synthetic adjuvant AS01B combined with low-dose intravenous (IV) nivolumab (NIVO) in advanced pretreated melanoma patients.
e21514 Background: Many advanced melanoma patients (pts) will not obtain a durable response on immune checkpoint- (ICI) an...
Association of early cognitive decline with compromised delivery of adjuvant chemotherapy.
11010 Background: Cancer-related cognitive impairment (CRCI, “chemobrain”) is a common condition among patients (pts) rece...
Outcome of chemotherapy among intubated patients with small cell lung cancer: A systematic review.
e20163 Background: Small cell lung cancer (SCLC) is characterized by rapid doubling time and early metastasis, often leadi...
Clinicopathological characteristics and prognosis of pheochromocytomas and paragangliomas (PPGLs) in 235 patients.
e15175 Background: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors. Clinical and pathological...
AGIBOT AM1000 versus da Vinci Xi systems for robot-assisted partial nephrectomy: A retrospective propensity score–matched noninferiority study.
e16540 Background: Robot-assisted partial nephrectomy (RAPN) has become a new standard option for clinical T1 renal tumors...
Real-world landscape of PTEN protein expression and its relationships with HER2 and PSMA in Chinese hormone-sensitive prostate cancer.
e17102 Background: This study aimed to characterize the prevalence of PTEN loss and explore its associations with HER2 and...
Bortezomib plus gemcitabine-cisplatin versus gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancers: A randomized phase II clinical trial with exploratory analysis of PTEN status.
4112 Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment and poor prognosis, inclu...
Germline genetic correlates in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus non-steroidal anti-androgen (NSAA) or enzalutamide (ENZA): Correlative study of ENZAMET (ANZUP 1304).
5099 Background: The international, randomized, phase III ENZAMET trial (n=1125) showed improved overall survival (OS) wit...
Perioperative therapy with tifcemailmab plus toripalimab and chemotherapy for resectable thoracic esophageal squamous cell carcinoma (BT-NICE trial): A prospective phase II study.
4087 Background: Tifcemailmab is a first-in-class humanized monoclonal antibody targeting B- and T-lymphocyte attenuator (...